Physician
Oncology
Dr. Gerald S. Falchook, MD
|
|
Give Review
Gerald S. Falchook, MD works in the field of Oncology. He went to medical school at Baylor College of Medicine. Gerald S. Falchook, MD has written publications. He has 95 publications published with PubMed. The lastest publication is: 'Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.' He accepts all Medicare patients.
Publications
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
- Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced Cancer.
- Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel deLivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
- Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced Melanoma.
- Phase I trial of valproic acid and lenalidomide in patients with advanced Cancer.
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung Cancer.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Olanzapine for cachexia in patients with advanced Cancer: an exploratory study of effects on weight and metabolic cytokines.
- BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid Tumors.
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab.
- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid Cancer.
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Outcomes of patients with advanced Cancer and KRAS mutations in phase I clinical trials.
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid Tumors.
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid Tumors.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study.
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid Tumors.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory Cancers: an open-label, phase 1 dose-escalation and expansion study.
- Evaluation of a novel blood pressure scoring method and its association with clinical response in Cancer patients treated with anti-vascular endothelial growth factor ...
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced Cancers.
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced Cancer.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with Liver metastases.
- A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on...
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Re...
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436).
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced Cancer.
- Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors.
- HER2-amplified salivary duct Carcinoma: Regression with dual HER2 inhibition and anti-VEGF combination treatment.
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy.
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid Tumors.
- Factors related to biopsy willingness in patients with advanced Cancer in a phase 1 clinic for molecularly targeted therapy.
- Non-Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment.
- BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for Analysis of acquired...
- Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung Cancer.
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
- A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid Tumors.
- Personalized medicine in a phase I clinical trials program: the MD anderson Cancer center initiative.
- Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the Liver.
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced Tumors: implications for therapy.
- Trametinib for patients with advanced Melanoma - Authors' reply.
- Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor.
- Activity of the oral MEK inhibitor trametinib in patients with advanced Melanoma: a phase 1 dose-escalation trial.
- Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience.
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors.
- Electrocardiograms (ECGs) in phase I antiCancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.
- KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors.
- Dabrafenib in patients with melanoma, untreated Brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
- Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
- Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience.
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience.
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center.
- Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel in Cancer Patients with Predominant Hepatic Metastases: Toxicity, Pharmacokinetics,...
- PIK3CA mutations in patients with advanced Cancers treated with PI3K/AKT/mTOR axis inhibitors.
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers.
- Patients with advanced head and neck Cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
- Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid Tumors.
- Clinicopathologic features and treatment strategies for patients with pancreatic adenoCarcinoma and ovarian metastases.
- Postmalaria neurological syndrome after treatment of Plasmodium falciparum malaria in the United States.
- Tuberculosis screening, referral, and treatment in an inner city homeless shelter in Orleans parish.
- Hepatosplenic gamma-delta T-Cell lymphoma: clinicopathological features and treatment.
- An index of topographic normality in rat somatosensory cortex: application to a sciatic nerve crush model.
- Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
- Phase I clinical trials in 85 patients with gynecologic Cancer: the M. D. Anderson Cancer Center experience.
- Outcome analyses after the first admission to an intensive care unit in patients with advanced Cancer referred to a phase I clinical trials program.
- Outcomes of research biopsies in phase I clinical trials: the MD anderson Cancer center experience.
- BRAF mutations in advanced Cancers: clinical characteristics and outcomes.
- Sensitivity of neurons in somatosensory cortex (S1) to cutaneous stimulation of the hindlimb immediately following a sciatic nerve crush.
- Retreatment after Secondary Resistance or Mixed Response: A Pilot Study.
- Phase I study of azacitidine and oxaliplatin in patients with advanced Cancers that have relapsed or are refractory to any platinum therapy.
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal Cancer.
- Dabrafenib for treatment of BRAF-mutant Melanoma.
- MET nucleotide variations and amplification in advanced ovarian Cancer: characteristics and outcomes with c-Met inhibitors.
- Dabrafenib.
- Next generation sequencing of exceptional responders with BRAF-mutant Melanoma: implications for sensitivity and resistance.
- Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel deLivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Schools
La State Univ Sch Of Med In New Orleans
Baylor College Of Med
University Texas M D Anderson Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Baylor College of Medicine -
Louisiana State University School of Medicine in New Orleans
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1366541294 | |
| NPPES Provider LastName | FALCHOOK | |
| NPPES Provider FirstName | GERALD | |
| NPPES Provider ZIPCode | 802181234 | |
| NPPES Provider State | CO | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 429.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 49.0 | |
| Percent Opioid Claims | 11.42 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1366541294 |
| Last Name Of The Provider | FALCHOOK |
| First Name Of The Provider | GERALD |
| View All |
Similar Doctors
|
|
Dr. Tapan M. Kadia, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Harry R. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberly H. Koenig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan M. Kurie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine M. Pisters, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Padmanee Sharma, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Uzma Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miloslav I. Beran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pierre Saintigny, MD
This Doctor is OpenDoctor Recommended.
|